INTERFERON-BETA TREATMENT AND DISABILITY PROGRESSION IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
We found no strong evidence that interferon-beta treatment was associated with a significant reduction of disability progression in patients with relapsing-remitting multiple sclerosis in an observational study from British Columbia, Canada. Our findings suggest realistic expectations regarding the impact of interferon-beta treatment on multiple sclerosis disability progression in the “real-world” setting.
Afsaneh Shirani
Vancouver, Ca